IGM Biosciences, Inc.
- Jurisdiction
United States - LEI
5493008XCQES2N0VY969 - ISIN
US4495851085 (IGMS )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Read full profile
Fundamentals
- Net revenue
€123.72M - Gross margin
98.1% - EBIT
-€23.76M - EBIT margin
-19.2% - Net income
-€45.53M - Net margin
-36.8%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
| N/A |
| |
| N/A |
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Decker Lisa Lynn | CHIEF BUSINESS OFFICER |
|
|
|
|
| Harler Mary Beth | Chief Executive Officer |
|
|
|
|
| Tahir Misbah | CHIEF FINANCIAL OFFICER |
|
|
|
|
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: March 31, 2023 (Q4 2022)